HIV in pregnancy: Mother-to-child transmission, pharmacotherapy, and toxicity

Biochim Biophys Acta Mol Basis Dis. 2021 Oct 1;1867(10):166206. doi: 10.1016/j.bbadis.2021.166206. Epub 2021 Jun 29.

Abstract

An estimated 1.3 million pregnant women were living with HIV in 2018. HIV infection is associated with adverse pregnancy outcomes and all HIV-positive pregnant women, regardless of their clinical stage, should receive a combination of antiretroviral drugs to suppress maternal viral load and prevent vertical fetal infection. Although antiretroviral treatment in pregnant women has undoubtedly minimized mother-to-child transmission of HIV, several uncertainties remain. For example, while pregnancy is accompanied by changes in pharmacokinetic parameters, relevant data from clinical studies are lacking. Similarly, long-term adverse effects of exposure to antiretrovirals on fetuses have not been studied in detail. Here, we review current knowledge on HIV effects on the placenta and developing fetus, recommended antiretroviral regimens, and pharmacokinetic considerations with particular focus on placental transport. We also discuss recent advances in antiretroviral research and potential effects of antiretroviral treatment on placental/fetal development and programming.

Keywords: Antiretroviral therapy; Fetal programming; HIV; Mother-to-child transmission; Placental membrane transporters; Placental/fetal development.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Retroviral Agents / pharmacology*
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / transmission*
  • Humans
  • Infectious Disease Transmission, Vertical / prevention & control*
  • Placenta / virology
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy
  • Pregnancy Complications, Infectious / virology

Substances

  • Anti-Retroviral Agents